Diagnostics
Regulatory delays often begin before submission: incomplete development evidence, inconsistent CMC and clinical documents, unclear market requirements, or weak lifecycle planning. Ariba & Mac provides regulatory affairs consulting in Saudi Arabia to help pharmaceutical, biotech and healthcare organizations define the pathway, identify dossier gaps and prepare submission-ready documentation around the next regulatory milestone.
For Saudi projects, our work is aligned with current SFDA registration requirements and coordinated with relevant clinical, CMC and quality workstreams. We also support CTD/eCTD dossier preparation, authority questions, labeling, variations, renewals and inspection readiness for regional and international pathways where these services are within the agreed project scope.
SFDA Regulatory Affairs Consulting & Global Submission Support
Support is scoped around the product, target authority and current development stage, from regulatory strategy and dossier gap assessment through submission, authority responses and post-approval lifecycle management.
- Saudi/SFDA regulatory strategy, pathway assessment and dossier gap analysis.
- CTD/eCTD and DMF authoring, compilation, quality control and publishing support for applicable submission types.
- Cross-functional alignment of Module 3/CMC, nonclinical and clinical documentation before submission.
- Health-authority questions, meeting preparation, response coordination and commitment tracking.
- Labeling, variations, renewals and post-approval change-control planning.
- Inspection-readiness document review, mock interviews and evidence-traceability checks.
- Regulatory intelligence and lifecycle planning for Saudi, regional and selected international markets.
eCTD/DMF Compilation & Publishing
Structure and quality-check dossier content, cross-references and lifecycle sequences using CTD/eCTD conventions appropriate to the target authority.
Agency Strategy & Meetings
Prepare briefing materials, questions, response packages and action tracking so authority interactions remain evidence-based and auditable.
Lifecycle & Labeling Management
Plan variations, renewals, labeling updates and post-approval commitments so approved product information and regulatory records remain controlled.
Regulatory Strategy, eCTD & Lifecycle Management Process
We start by defining the product, markets, submission objective and evidence gaps, then map responsibilities across regulatory, CMC, clinical and quality teams. Dossier structure follows ICH CTD principles where applicable, while Saudi submissions are checked against current SFDA requirements and lifecycle expectations.
- Proactive engagement with authorities to clarify expectations.
- ICH, GxP, and data integrity (ALCOA+) built into every submission.
Inspection Readiness
Mock audits, evidence-traceability reviews and interview preparation help teams identify documentation gaps before an authority inspection or formal review.
Proactive Approach
Early alignment between regulatory, clinical, CMC and quality workstreams reduces late-stage dossier rework and conflicting commitments.
Saudi & Global Regulatory Submission Support
Projects may require a combination of in-house regulatory work and specialist publishers, translators or regional agents. We coordinate those workstreams under defined responsibilities and change control, including current SFDA variation requirements for Saudi lifecycle activities where relevant.
Dossier Development
Author, review and coordinate Modules 1–5 content with consistent document control, cross-references and submission readiness checks.
Agency Engagement
Prepare meetings and responses, assign owners and track questions, commitments and evidence through closure.
Post‑Approval Support
Coordinate renewals, variations, labeling and pharmacovigilance-related regulatory updates within the agreed lifecycle scope.
Regulatory Affairs Consulting FAQs
Services can include regulatory strategy, SFDA pathway assessment, CTD/eCTD dossier support, authority interactions, labeling, variations, renewals, inspection readiness and lifecycle planning. The exact scope depends on the product, market and development stage.
We can coordinate dossier planning, document readiness, CTD/eCTD structure, cross-functional content collection, quality control and publishing support. Before submission, gaps and inconsistencies are tracked so CMC, nonclinical and clinical sections tell a coherent regulatory story.
Our experience covers Saudi SFDA and selected regional and international pathways, including FDA, EMA, MHRA, GCC/GHC and DRAP-related work where relevant to the project. Authority-specific requirements are confirmed during scoping rather than assumed to be identical across markets.
We establish a change-control and submission plan for each market, identify the required supporting evidence, coordinate updated product information and track authority submissions and commitments. For Saudi products, current SFDA variation and renewal requirements are checked as part of the lifecycle plan.
We review the evidence trail, document controls, key procedures and open actions, then use mock interviews or readiness reviews to identify gaps before inspection. Consultancy support improves preparedness but does not guarantee an authority outcome or approval.